Additionally, inhibition of ADAM10 prevents the release of NLGN3 into the TME, thereby suppressing high-grade glioma xenograft growth by blocking NLGN3-mediated activation of the phosphoinositol 3-kinase (PI3K)/mechanistic target of rapamycin (mTOR) signaling pathway. Here, MTOR is linked to central nervous system cancer.